31results about "Neuregulins" patented technology

To provide a method of treating a patient with chronic heart failure using a medicament comprising neuregulin.SOLUTION: A companion diagnostic test is first performed on each patient prior to treatment, and the appropriate treatment is provided to each patient according to the companion diagnostic test results. If the test results are within a preferred therapeutic range for treatment, the patient is suitable for treatment of heart failure by administration of an effective amount of neuregulin.SELECTED DRAWING: None

There is provided a recombinant adeno-associated virus (rAAV) vector comprising one or both of (a) to (c): (a) a nucleotide sequence encoding an aromatic L-amino acid decarboxylase (AADC); (b) a nucleotide sequence for encoding glucocerebrosidase (GBA1); and (c) a nucleotide sequence encoding a neurotrophic factor (NTF), such as brain dopamine neurotrophic factor (CDNF) or glial cell-derived neurotrophic factor (GDNF), for use in the treatment of neurodegenerative disorders, in particular Parkinson's disease (PD), Multi-System Atrophy (MSA), Gaucher's disease (GD) and other proteinopathies. Also provided herein are viral particles comprising the rAAV vector, pharmaceutical compositions comprising the viral particles, and uses thereof.

Disclosed is a use of recombinant human neuregulin derivatives in preparing a medicine for preventing, treating, or reducing the progression of cardiovascular diseases in mammals. In particular, the present invention relates to a novel recombinant human NRG-FC protein and a use thereof in the treatment of cardiovascular diseases. The protein has a prolonged half-life and enhanced biological activity.

The present invention provides a pharmaceutical product for use in preventing, treating, or mitigating myocardial injury in mammals. [Solution] The use of neuregulin (NRG) in the manufacture of a pharmaceutical product for use in preventing, treating, or mitigating myocardial injury in mammals, wherein the method includes subcutaneous administration of the NRG to the mammal multiple times a day at a dose of approximately 30 μg / kg / day for several consecutive days, and then slowly discontinuing the NRG after the administration by reducing the daily dose over three weeks, wherein the daily dose in the first week is half of the administered dose, the daily dose in the second week is one-quarter of the administered dose, and the daily dose in the third week is one-eighth of the administered dose.

The present invention relates to compositions and methods of GDNF fusion polypeptides, wherein the GDNF fusion polypeptides include an Fc domain, an albumin-binding peptide, a fibronectin domain, or a human serum albumin, joined to a GDNF variant either directly or by the way of a linker. The GDNF fusion polypeptides may used to treat metabolic diseases, such as obesity and Type-1 and Type-2 diabetes, and neurological diseases, such as Amyotrophic lateral sclerosis (ALS) and Parkinson's disease.

The present disclosure relates to a fusion protein comprising a neurotrophin and a monomeric Ig Fc domain or fragment thereof, and methods of manufacturing the same.

Provided are a nucleic acid construct for achieving modular loading of an engineered EVs functional protein and use of said construct. A modular design principle is adopted, specific modules are selected for combination, a mutant sequence is optimized and screened to obtain an improved nucleic acid construct, and finally, the engineered EVs modularly loaded with functional protein is converted and expressed. The product has the following advantages that: I) the modular loading of the engineered EVs functional protein is achieved; 2) the loading density and the loading efficiency of the protein inside and outside an EVs membrane are improved; and 3) a specific support sequence module is selected to avoid enzyme digestion. The construct is used to prepare the engineered EVs, so that the modular loading of the functional protein can be achieved, the loading efficiency is improved, and the construct has a wide clinical application value and market prospect.

The present invention relates to compositions and methods of GDNF fusion polypeptides, wherein the GDNF fusion polypeptides include an Fc domain, an albumin-binding peptide, a fibronectin domain, or a human serum albumin, joined to a GDNF variant either directly or by the way of a linker. The GDNF fusion polypeptides may used to treat metabolic diseases, such as obesity and Type-1 and Type-2 diabetes, and neurological diseases, such as Amyotrophic lateral sclerosis (ALS) and Parkinson's disease.

Disclosed herein are designer extracellular vesicles (EVs) that target Schwann cells (SCs). For example, in some embodiments, the EVs are decorated with HRG1 / 2, NRG1, or a combination thereof. In some embodiments, these EVs can be used to deliver diagnostic and / or therapeutic cargo to Schwann cells of a subject in need thereof.

To provide drugs and methods for preventing, treating or delaying human heart failure.SOLUTION: A method for treating chronic heart failure patient using an agent comprising neuregulin is provided. The method comprises conducting a companion diagnostic test of each patient prior to the treatment, and according to the test result of the companion diagnostic test, a treatment suitable for the patient is provided. When the test result is within a preferred treatment zone, the patient is suitable for the heart failure treatment by administering an effective amount of neuregulin.SELECTED DRAWING: None

The present application relates to the technical field of central obesity related research and treatment, by constructing a central obesity mouse model, it is found that the up-regulation of brain-derived neurotrophic factor (BDNF) expression in adipose tissue is closely related to central obesity resistance. A BDNF fusion polypeptide composed of TAT cell-penetrating peptide, flexible linker and BDNF mature peptide is designed and prepared, the fusion polypeptide has strong cell viability promoting effect at the cellular level, can effectively activate the BDNF signaling pathway and has better stability than natural BDNF protein; an anti-TrkB monoclonal antibody with high affinity and high titer is also prepared. In vivo experiments show that the BDNF fusion polypeptide and its combination with the anti-TrkB monoclonal antibody can effectively inhibit the weight gain of central obesity mice, improve glucose metabolism disorder, increase serum BDNF level and activate the TrkB signaling pathway, and the combination has better synergistic therapeutic effect, which provides a new direction and experimental basis for the treatment of central obesity.

Provided are recombinant adeno-associated virus (rAAV) vectors comprising one or two of (a) to (c): (a) a nucleotide sequence encoding an aromatic L-amino acid decarboxylase (AADC); (b) a nucleotide sequence encoding a glucocerebrosidase (GBA1); and (c) a nucleotide sequence encoding a neurotrophic factor (NTF) such as a brain dopamine neurotrophic factor (CDNF) or a glial cell-derived neurotrophic factor (GDNF), for use in the treatment of neurodegenerative disorders, in particular Parkinson’s disease (PD), multiple system atrophy (MSA), Gaucher’s disease (GD), and other proteinopathies. Also provided herein are viral particles comprising the rAAV vectors, pharmaceutical compositions comprising the viral particles, and uses thereof.

In one aspect, methods of promoting asymmetric nerve growth and / or regeneration are described herein. In some embodiments, such a method comprises exposing a population of transected or severed nerves to a first molecular growth cue and to a second molecular growth cue. The population of transected nerves comprises one or more nerves of a first nerve type and one or more nerves of a second nerve type differing from the first nerve type. Additionally, the first molecular growth cue preferentially promotes growth of the first nerve type, as compared to the second nerve type. Similarly, the second molecular growth cue preferentially promotes growth of the second nerve type, as compared to the first nerve type. Moreover, the first molecular growth cue is spatially separated from the second molecular growth cue.

The application belongs to the technical field of biological drugs, and particularly relates to a preparation method of genetically modified human bone marrow mesenchymal stem cells and application thereof in treating nervous system diseases, in particular, multiple sclerosis. The human bone marrow mesenchymal stem cells are double-modified by brain-derived neurotrophic factor (BDNF) and anti-S1PR5 nanobody, so that the activity of the human bone marrow mesenchymal stem cells is improved, the survival of neurons or oligodendrocytes is promoted, cell apoptosis is inhibited, and myelin regeneration is promoted, and the human bone marrow mesenchymal stem cells can be applied to nervous system diseases, in particular, multiple sclerosis.

Provided are recombinant adeno-associated virus (rAAV) vectors comprising one or two of (a) to (c): (a) a nucleotide sequence encoding an aromatic L-amino acid decarboxylase (AADC); (b) a nucleotide sequence encoding a glucocerebrosidase (GBA1); and (c) a nucleotide sequence encoding a neurotrophic factor (NTF) such as a brain dopamine neurotrophic factor (CDNF) or a glial cell-derived neurotrophic factor (GDNF), for use in the treatment of neurodegenerative disorders, in particular Parkinson’s disease (PD), multiple system atrophy (MSA), Gaucher’s disease (GD), and other proteinopathies. Also provided herein are viral particles comprising the rAAV vectors, pharmaceutical compositions comprising the viral particles, and uses thereof.

Aspects of the present disclosure relate generally to chimeric proteins and pharmaceutical compositions comprising such chimeric proteins, and methods for using such chimeric proteins for treating acute radiation syndrome in subjects in thereof.

Provided are a nucleic acid construct for achieving modular loading of an engineered EVs functional protein and use of said construct. A modular design principle is adopted, specific modules are selected for combination, a mutant sequence is optimized and screened to obtain an improved nucleic acid construct, and finally, the engineered EVs modularly loaded with functional protein is converted and expressed. The product has the following advantages that: I) the modular loading of the engineered EVs functional protein is achieved; 2) the loading density and the loading efficiency of the protein inside and outside an EVs membrane are improved; and 3) a specific support sequence module is selected to avoid enzyme digestion. The construct is used to prepare the engineered EVs, so that the modular loading of the functional protein can be achieved, the loading efficiency is improved, and the construct has a wide clinical application value and market prospect.

To provide optimized or improved neuregulin (NRG) for use in preventing, treating, or reducing cardiovascular diseases.SOLUTION: Disclosed is a use of recombinant human neuregulin derivatives in preparing a medicine for preventing, treating, or reducing the progression of cardiovascular diseases in mammals. In particular, the present invention relates to a novel recombinant human NRG-FC protein and a use thereof in the treatment of cardiovascular diseases. The protein has a prolonged half-life and enhanced biological activity.SELECTED DRAWING: None

The present invention generally relates to uses of glial cell line-derived growth factor (GDNF) in cutaneous wound healing and hair growth. Methods of effecting hair growth and / or wound healing which feature administration of GDNF, or a biologically active fragment thereof, to subjects, e.g., human subject, are disclosed herein. The invention relates also to formulations and kits for achieving the indicated pharmaceutical advantages.

Provided is a recombinant adeno-associated viral (rAAV) vector comprising one or two of (a) to (c): (a) a nucleotide sequence encoding aromatic L-amino acid decarboxylase (AADC), (b) a nucleotide sequence encoding glucocerebrosidase (GBA1); and (c) a nucleotide sequence encoding a neurotrophic factor (NTF), such as cerebral dopamine neurotrophic factor (CDNF) or glial cell derived neurotrophic factor (GDNF), for treating neurodegenerative disorders, particularly Parkinson's disease (PD), Multiple system atrophy (MSA), Gaucher's disease (GD), and other proteinopathies. Also provided herein are viral particles comprising the rAAV vector, a pharmaceutical composition comprising the viral particles, and uses thereof.

A method and kit for treating a neurodegenerative disease or central nervous system disorder in a subject using a GlyB4 fusion protein is provided, as is a kit containing the same.

The invention provides neuregulin for use in a method of treating chronic heart failure in a patient having a class II or class III heart function as classified by New York Heart Association (NYHA) heart function classification. The invention also provides a method of selecting a heart failure patient for treatment by neuregulin, which comprises: (i) evaluating heart function class by NYHA heart function classification, and (ii) deciding whether the result of the test is indicative for the treatment by neuregulin, wherein the result of the test is indicative for the treatment by neuregulin when the patient has a class II or class III heart function.

There is provided a recombinant adeno-associated virus (rAAV) vector comprising one or both of (a) to (c): (a) a nucleotide sequence encoding an aromatic L-amino acid decarboxylase (AADC); (b) a nucleotide sequence for encoding glucocerebrosidase (GBA1); and (c) a nucleotide sequence encoding a neurotrophic factor (NTF), such as brain dopamine neurotrophic factor (CDNF) or glial cell-derived neurotrophic factor (GDNF), for use in the treatment of neurodegenerative disorders, in particular Parkinson's disease (PD), Multi-System Atrophy (MSA), Gaucher's disease (GD) and other proteinopathies. Also provided herein are viral particles comprising the rAAV vector, pharmaceutical compositions comprising the viral particles, and uses thereof.

The present invention provides an artificially designed novel NRG-1 nucleic acid molecule, a protein variant thereof, a vector, a vaccine, a cell, a pharmaceutical composition, and a protein composition. Also provided are a method for using the product to produce a protein and a primary RNA polynucleotide, and a use in preparation of a product for preventing, alleviating or treating cardiovascular diseases and neurological diseases, a product for maintaining normal functions of heart cells or tissues, and a vaccine.

The present invention relates to a recombinant fusion protein comprising a fragment of the cardioprotective protein Neuregulin-1 (NRG-1) fused to a HER3 monoclonal antibody (mAb) backbone, and a method for treating atrial fibrillation and / or cardiac fibrosis in a subject in need of such treatment comprising administering a therapeutically effective amount of the recombinant fusion protein disclosed herein or a pharmaceutical composition comprising said recombinant fusion protein.

To provide a method and a composition for preventing, treating or delaying myocardial injury in mammals.SOLUTION: Provided are an administration method for, an administration frequency of and an administration dosage of a pharmaceutical formulation or composition for reducing myocardial damage, using neuregulin. It can be proved in a rat myocardial damage model that neuregulin can improve the cardiac function after myocardial infarction, suggesting that neuregulin can be used for preventing, treating or delaying myocardial infarction damage.SELECTED DRAWING: None

There is provided a recombinant adeno-associated virus (rAAV) vector comprising one or both of (a) to (c): (a) a nucleotide sequence encoding an aromatic L-amino acid decarboxylase (AADC); (b) a nucleotide sequence for encoding glucocerebrosidase (GBA1); and (c) a nucleotide sequence encoding a neurotrophic factor (NTF), such as brain dopamine neurotrophic factor (CDNF) or glial cell-derived neurotrophic factor (GDNF), for use in the treatment of neurodegenerative disorders, in particular Parkinson's disease (PD), Multi-System Atrophy (MSA), Gaucher's disease (GD) and other proteinopathies. Also provided herein are viral particles comprising the rAAV vector, pharmaceutical compositions comprising the viral particles, and uses thereof.

Provided herein are recombinant fusion proteins comprising an active fragment of neuregulin-1 (NRG-1) fused to a monospecific ErbB3 (HER3) monoclonal antibody (mAb), and methods of using same to treat cardiovascular disease.

The present invention relates to a human proBDNF mutein and to a method of recombinantly producing a biologically active human brain-derived neurotrophic factor (BDNF).

Provided is a recombinant adeno-associated viral (rAAV) vector comprising one or two of (a) to (c) : (a) a nucleotide sequence encoding aromatic L-amino acid decarboxylase (AADC), (b) a nucleotide sequence encoding glucocerebrosidase (GBA1); and (c) a nucleotide sequence encoding a neurotrophic factor (NTF), such as cerebral dopamine neurotrophic factor (CDNF) or glial cell derived neurotrophic factor (GDNF), for treating neurodegenerative disorders, particularly Parkinson's disease (PD), Multiple system atrophy (MSA), Gaucher's disease (GD), and other proteinopathies. Also provided herein are viral particles comprising the rAAV vector, a pharmaceutical composition comprising the viral particles, and uses thereof.